摘要
目的研究MYL9在前列腺癌组织中的表达水平与前列腺癌临床预后的相关性。方法采用免疫组织化学检测80例前列腺癌根治术患者前列腺癌及61例癌旁良性前列腺组织中的MYL9的表达水平,并与前列腺癌(PCa)患者的临床特征相比较。结果在良性和前列腺癌组织中,MYL9均主要在前列腺间质而不是在前列腺上皮细胞表达,前列腺癌样本中的MYL9表达水平相对于良性前列腺组织显著下调(PCa=3.21±1.46 vs.Benign=4.63±0.97,P<0.001)并伴有肿瘤间质容积的明显减少。MYL9的下调表达与前列腺癌的Gleason评分(P<0.001)明显相关。结论表明MYL9表达下调越明显,则前列腺癌患者临床预后越差。该研究为MYL9在前列腺癌组织中的下调表达可作为预测人类前列腺癌患者的不良临床预后的指标提供了证据。
Objective To investigate the association of MYL9 expression with tumor progression and prognosis in patients with prostate cancer （PCa）. Methods MYL9 protein expressions in human PCa and non-cancerous prostate tissues were detected by immunohistochemistry analyses. Then,the associations of MYL9 expression with clinicopathological features and clinical outcome of PCa patients were statistically analyzed. Results Immunohistochemistry analyses showed that MYL9 expression significantly decreased in PCa tissues as compared with those in non-cancerous prostate tissues. In addition, MYL9 was mainly expressed in the cytoplasm of stromal cells of prostate tissues, and the decreased expression of MYL9 in PCa tissues was significantly correlated with the higher Gleason score. Conclusion Our data strongly confirmed for the first time that the decreased expression of MYL9 may play an important role in tumor progression of PCa.
出处
《岭南现代临床外科》
2014年第4期358-361,共4页
Lingnan Modern Clinics in Surgery
基金
国家自然科学基金(编号:81272813
81200550)
广东省科技计划项目(编号:2012B031800008)
